Should Left Atrial Appendage Occlusion Devices Be Routinely Used Instead of Oral Anticoagulants to Prevent Thromboembolic Events, Stroke, and Bleeding for Patients With Non‐Valvular Atrial Fibrillation?
- 8 September 2026
- journal article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2403-2408
Abstract
Introduction: Oral anticoagulants (OACs), preferably direct (D)/non‐vitamin K (N) dependent OACs [DOACs/NOACs] are recommended for the management of patients with non‐valvular atrial fibrillation (AF) at risk for thromboembolic events, including stroke. Left atrial appendage occlusion (LAAO) device implantation has been considered for patients who are unsuitable for OACs or prefer not to take them. Herein, we discuss the clinical evidence for routine use of LAAO instead of OACs for patients with AF at risk of thromboembolic events, stroke, and bleeding. Method: From pertinent, recent, randomized clinical trials, the CHAMPION‐AF (Watchman Flx vs. NOAC for Embolic Protection in the Management of Patients with Non‐Valvular Atrial Fibrillation), and CLOSURE‐AF (Catheter‐Based Left Atrial Appendage Closure in Patients with Atrial Fibrillation at High Risk of Stroke and Bleeding as Compared with Best Medical Therapy) were selected for review. Results: As interpreted by the authors of the CHAMPION‐AF trial, LAAOs were considered non‐inferior to NOACs at 3 years. In the CLOSURE‐AF trial, non‐inferiority criteria were not met. For safety, that is, bleeding, LAAO was considered superior in CHAMPION‐AF. We found several points related to both trials that are critical to interpret the results and clinical implications of these trials. These points are particularly related to the interpretation of non‐inferiority trial design, selection bias, combined primary endpoint, bleeding and peri‐procedural bleeding complications, serious adverse events, cross‐over rates, sub‐group analyses, conflicts of interest, and mechanism of stroke. Conclusion: Data from the CHAMPION‐AF and CLOSURE trials do not favor routine and widespread use of LAAO devices in non‐valvular AF patients over use of OACs.Keywords
This publication has 17 references indexed in Scilit:
- Left Atrial Appendage Closure or Anticoagulation for Atrial FibrillationNew England Journal of Medicine, 2026
- Left Atrial Appendage Closure or Medical Therapy in Atrial FibrillationNew England Journal of Medicine, 2026
- Left Atrial Appendage Occlusion Versus NOACs in patients With Atrial Fibrillation: Rationale and Design of the CATALYST TrialAmerican Heart Journal, 2026
- Antithrombotic Therapy after Successful Catheter Ablation for Atrial FibrillationNew England Journal of Medicine, 2026
- Left Atrial Appendage Closure after Ablation for Atrial FibrillationNew England Journal of Medicine, 2025
- 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2024
- Atrial cardiomyopathy revisited—evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS)EP Europace, 2024
- Assessment of Noninferiority Margins in Cardiovascular Medicine TrialsJACC: Advances, 2024
- Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia SocietyJournal of Interventional Cardiac Electrophysiology, 2022
- The NCDR Left Atrial Appendage Occlusion RegistryJACC, 2020